Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cabozantinib + Immunotherapy for Cancer
Recruiting1 awardPhase 2
Toronto, Ontario
This trial is studying a combination of drugs to treat neuroendocrine tumors. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Nivolumab and ipilimumab are immunotherapy drugs that help the body's immune system attack the cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service